In addition to these encouraging data, the study by Hansen et al.33 suggests an important predictive value of EGFL7-positive vascular area in relation to first-line chemotherapy and bevacizumab for CRC and suggests the use of a dual VEGFA-EGFL7 blocking mechanism. This evidence concerns the gene EGFL7 and colorectal carcinoma.